Sutro BioPharma, Inc.
NASDAQ: STROSouth San Francisco, US · Founded 2003 · Delaware corporation · 198 employees on LinkedIn · 1 known investors
Clinical-stage company developing next generation antibody drug conjugates for cancer treatment using proprietary cell-free protein manufacturing technology.
Founders & leadership
WJ
William J. NewellExecutive
JL
Joseph LobackiNamed on SEC filing
VB
Virgil Bryan LawlisNamed on SEC filing
MR
Michael RossNamed on SEC filing
DP
Daniel PetreeNamed on SEC filing
Board
DJ
Daniel JanneyBoard director
AS
Armen ShanafeltBoard director
JG
John G. FreundBoard director
MD
Investors · 1
Reported raises · per SEC filings
Form D private placements$85.4M disclosed across 1 round · 2018
▶$85.4MraisedAug 2018 · 15 investors · BiotechnologyRule 506(b)
▶$85.4MraisedAug 2018 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Joseph LobackiDirector
- Daniel JanneyDirector
- Armen ShanafeltDirector
- Virgil Bryan LawlisDirector
- John G. FreundDirector
- William J. NewellExecutive Officer, Director
- Michael DybbsDirector
- Michael RossDirector
- Daniel PetreeDirector
- Offering amount
- $85.4M
- Amount sold
- $85.4M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Sutro BioPharma, Inc. do?
- Clinical-stage company developing next generation antibody drug conjugates for cancer treatment using proprietary cell-free protein manufacturing technology.
- Who are Sutro BioPharma, Inc.'s investors?
- Sutro BioPharma, Inc.'s investors include Samsara BioCapital.
- How much funding has Sutro BioPharma, Inc. raised?
- Sutro BioPharma, Inc. has disclosed $85.4M raised across 1 round.
- Where is Sutro BioPharma, Inc. headquartered?
- Sutro BioPharma, Inc. is headquartered in South San Francisco, US.